New PET tracer aims to light up head and neck tumors
NCT ID NCT03631017
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial is testing the safety of a new imaging drug called [18F]PARPi in 12 people with head and neck cancer. The drug is designed to make cancer cells show up more clearly on PET/CT scans. The goal is to see if this approach can provide better pictures of tumors than current standard imaging methods.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- [18F]PARPi (a radioactive imaging agent)
- What this could lead to
- If successful, this could lead to a new, more precise way to image head and neck cancers using a PET scan.
- What could go wrong
- This is a very early, small study (12 people) focused on safety and imaging quality, not treatment. The imaging agent may not work as hoped or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tailored nutrition boost recovery from head and neck surgery?
- Can less radiation be safer for throat cancer?
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new drug boost the power of chemoradiation against head and neck cancer?
- Exercise after cancer therapy: a new way to gauge prognosis?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?